Search company, investor...

Predict your next investment

Venture Capital
FINANCE | Asset/Financial Management
sofinnovapartners.com

Investments

381

Portfolio Exits

76

Funds

17

Partners & Customers

2

About Sofinnova Partners

Sofinnova Partners is a European venture capital firm specializing in Life Sciences. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs. The company was founded in 1972 and is based in Paris, France.

Headquarters Location

17, rue de Surène

Paris, 75008,

France

+33 (0)1 5305-4100

Want to inform investors similar to Sofinnova Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Sofinnova Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Sofinnova Partners in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Sofinnova Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sofinnova Partners in 2 CB Insights research briefs, most recently on Jun 16, 2022.

Latest Sofinnova Partners News

The French Biotech Company Amolyt Pharma Raises €130 Million

Feb 2, 2023

In detail, this new financing was led by Sofinnova Partners and co-managed by Intermediate Capital Group, but the transaction also benefited from the participation of historical investors such as Andera Partners, Novo Holdings, Kurma Partners, EQT Life Science, and the Innobio 2 fund of Bpifrance Investissement. New investors also contributed to the €130 million investment. 0 Amolyt Pharma is a Lyon-based biotech specializing in rare endocrine diseases that develops a treatment for hypoparathyroidism and acromegaly. This start-up has just completed the largest fundraising in the history of the biotech sector in France Read more about Amolyt Pharma’s latest financing round and find the most important business headlines of the day with our companion app Born2Invest. Amolyt Pharma is a biotech expert in rare diseases Founded in 2015, Amolyt Pharma specializes in treatments for rare endocrine diseases. It currently has two drug candidates: AZP-3813, for the treatment of acromegaly, and, most importantly, AZP-3601, known as eneboparatide and aimed at curing hypoparathyroidism (a rare disease causing a lack of production of parathyroid hormone, which is involved in the regulation of calcium levels). Having completed Phase 2 of the latter treatment in September with positive results on its safety and efficacy, all funding will be focused on AZP-3601. Amolyt Pharma is counting on this new round of financing to fund its phase 3. This phase will include around 100 patients and is due to start in the first half of this year. “We have the financial resources to successfully complete this stage, which should lead to a marketing application in 2025, primarily in the United States,” said Thierry Abribat, founder and CEO of Amolyt Pharma. Amolyt Pharma closes a €130 million financing round After having raised €67 million in the previous round co-led by the American Sectoral Asset Management and Andera Partners, the Lyon-based biotech company has closed a €130 million Series C round, the largest in the history of biotechs in France. In detail, this new financing was led by Sofinnova Partners and co-managed by Intermediate Capital Group, but the transaction also benefited from the participation of historical investors such as Andera Partners, Novo Holdings, Kurma Partners, EQT Life Science, and the Innobio 2 fund of Bpifrance Investissement. New investors also contributed to the €130 million investment with funds managed by Tekla Capital Investment LLC, and CTI Life Sciences. Finally, Thierry Abribat welcomed the financing: “We are very pleased to complete this important Series C financing which will allow us, on the basis of our positive clinical results with enneboparatide, to accelerate the growth of Amolyt Pharma and its portfolio at the international level”. In conclusion, this new round of financing for Amolyt Pharma will enable the Lyon-based biotech company to accelerate its growth, particularly internationally, by capitalizing on the recent success of its phase 2 treatment. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  Planete GRANDE ECOLES , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Sofinnova Partners Investments

381 Investments

Sofinnova Partners has made 381 investments. Their latest investment was in Julier Medical as part of their Seed VC on January 1, 2023.

CBI Logo

Sofinnova Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/23/2023

Seed VC

Julier Medical

$3.26M

Yes

2

1/6/2023

Series C

Amolyt Pharma

$138.38M

Yes

7

12/19/2022

Series B

EnginZyme

$22.34M

No

16

12/2/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/23/2023

1/6/2023

12/19/2022

12/2/2022

11/29/2022

Round

Seed VC

Series C

Series B

Series A

Series B

Company

Julier Medical

Amolyt Pharma

EnginZyme

Subscribe to see more

Subscribe to see more

Amount

$3.26M

$138.38M

$22.34M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

7

16

10

10

Sofinnova Partners Portfolio Exits

76 Portfolio Exits

Sofinnova Partners has 76 portfolio exits. Their latest portfolio exit was Odoo on June 08, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/8/2022

Shareholder Liquidity

$99M

1

5/2/2022

Acquired

$99M

1

1/7/2022

IPO

$99M

Public

4

11/17/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/8/2022

5/2/2022

1/7/2022

11/17/2021

9/29/2021

Exit

Shareholder Liquidity

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

4

10

10

Sofinnova Partners Acquisitions

1 Acquisition

Sofinnova Partners acquired 1 company. Their latest acquisition was NovusPharma on September 20, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/1999

Convertible Note

$99M

Management Buyout

1

Date

9/20/1999

Investment Stage

Convertible Note

Companies

Valuation

$99M

Total Funding

Note

Management Buyout

Sources

1

Sofinnova Partners Fund History

17 Fund Histories

Sofinnova Partners has 17 funds, including Sofinnova Industrial Biotech II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/17/2021

Sofinnova Industrial Biotech II

$169.61M

1

10/19/2021

Sofinnova Capital X

$549.69M

1

7/13/2021

MD Start III

$75M

2

3/3/2021

Sofinnova Crossover Fund

$99M

10

10/17/2019

Sofinnova Capital IX

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

11/17/2021

10/19/2021

7/13/2021

3/3/2021

10/17/2019

Fund

Sofinnova Industrial Biotech II

Sofinnova Capital X

MD Start III

Sofinnova Crossover Fund

Sofinnova Capital IX

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$169.61M

$549.69M

$75M

$99M

$99M

Sources

1

1

2

10

10

Sofinnova Partners Partners & Customers

2 Partners and customers

Sofinnova Partners has 2 strategic partners and customers. Sofinnova Partners recently partnered with Apollo on May 5, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

5/16/2022

Partner

United States

Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences

NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership .

2

2/28/2018

Partner

Italy

Subscribe to see more

Subscribe to see more

10

Date

5/16/2022

2/28/2018

Type

Partner

Partner

Business Partner

Country

United States

Italy

News Snippet

Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences

NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership .

Subscribe to see more

Subscribe to see more

Sources

2

10

Sofinnova Partners Team

12 Team Members

Sofinnova Partners has 12 team members, including current Chief Financial Officer, Christophe Blanche.

Name

Work History

Title

Status

Christophe Blanche

Iris Capital, and PwC

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Christophe Blanche

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Iris Capital, and PwC

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.